NGL Fine Chem

Who are in the management team of NGL Fine Chem?

As of March 2023, the management team of NGL Fine Chem includes Rahul J Nachane (Managing Director), Rajesh N Lawande (Whole Time Director & CFO), Milind V Shinde (Chairman & Independent Director), Ajita Nachane (Non-Executive Director), Jayaram Sitaram (Non-Executive Independent Director), Pallavi Pednekar (Company Secretary), and Sarala Menon (Independent Director). They oversee the company's operations and strategic direction.

As of March 2023, the management team of NGL Fine Chem includes the following individuals:<BR><BR>1. Rahul J Nachane - Managing Director<BR>2. Rajesh N Lawande - Whole Time Director & CFO<BR>3. Milind V Shinde - Chairman & Independent Director<BR>4. Ajita Nachane - Non-Executive & Non-Independent Director<BR>5. Jayaram Sitaram - Non-Executive & Independent Director<BR>6. Pallavi Pednekar - Company Secretary & Compliance Officer<BR>7. Sarala Menon - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Has NGL Fine Chem declared dividend?

NGL Fine Chem Ltd has declared a 35% dividend, amounting to ₹1.75 per share, with an ex-date of August 16, 2024. While recent total returns have been negative, the company has shown significant positive returns over the past five years.

NGL Fine Chem Ltd has declared a 35% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 35%<BR>- Amount per share: 1.75<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 0.17%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -42.05%, with a dividend return of 0%, resulting in a total return of -42.05%.<BR><BR>Over the 1 year period, the price return was -53.0%, accompanied by a dividend return of 0.07%, leading to a total return of -52.93%.<BR><BR>For the 2 years period, the price return was -27.5%, with a dividend return of 0.21%, culminating in a total return of -27.29%.<BR><BR>In the 3 years period, the price return was -41.37%, and the dividend return was 0.21%, resulting in a total return of -41.16%.<BR><BR>During the 4 years period, the price return was -44.93%, with a dividend return of 0.34%, leading to a total return of -44.59%.<BR><BR>In the 5 years period, the price return was 163.89%, accompanied by a dividend return of 2.62%, resulting in a total return of 166.51%.<BR><BR>Overall, while NGL Fine Chem has declared a dividend, the total returns over the shorter periods have been negative, indicating a challenging performance. However, the longer-term returns over five years show a significant positive return, suggesting potential recovery or growth in the future.

Who are the peers of the NGL Fine Chem?

NGL Fine Chem's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Venus Remedies, Shukra Pharma, Nectar Lifesci, Medicamen Biotec, and Sakar Healthcare. NGL Fine Chem has average management risk, below-average growth, and the lowest 1-year return at -52.32% among its peers.

Peers: The peers of NGL Fine Chem are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Venus Remedies, Shukra Pharma., Nectar Lifesci., Medicamen Biotec, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average management risk is found at NGL Fine Chem, Venus Remedies, Shukra Pharma., Medicamen Biotec, and Sakar Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at NGL Fine Chem, Divi's Lab., Torrent Pharma, Nectar Lifesci., and Medicamen Biotec. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, NGL Fine Chem, Venus Remedies, and Medicamen Biotec, while Good capital structure is noted for Torrent Pharma and Shukra Pharma., and Average for Sakar Healthcare.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while NGL Fine Chem has the lowest at -52.32%. NGL Fine Chem's return is significantly lower than all its peers. Additionally, Nectar Lifesci., Medicamen Biotec, and NGL Fine Chem have negative six-month returns.

What does NGL Fine Chem do?

NGL Fine Chem Ltd is a Micro Cap manufacturer of pharmaceuticals and intermediates for veterinary and human health, with net sales of 950 Cr and a net profit of 5 Cr as of March 2025. The company was incorporated in 1981 and is based in Mumbai, India.

Overview:<BR>NGL Fine Chem Ltd is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>NGL Fine Chem Ltd was incorporated on December 18, 1981, initially as a Private Limited Company in Maharashtra and later became a Public Limited Company. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 950 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 5 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 891 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 43.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.13% <BR>Debt-Equity: 0.03 <BR>Return on Equity: 7.38% <BR>Price to Book: 3.00 <BR><BR>Contact Details:<BR>Address: 301 E Square Subhash Road, Vile Parle (East) Mumbai Maharashtra : 400057 <BR>Tel: +91-22-2663 6450 <BR>Email: cs@nglfinechem.com / info@nglfinechem.com <BR>Website: http://www.nglfinechem.com

Who are the top shareholders of the NGL Fine Chem?

The top shareholder of NGL Fine Chem is Rajesh Lawande, holding 21.89%, with no pledged promoter holdings. Public shareholders include Yashkumar Poonamchand Golechha at 1.05%, while individual investors collectively hold 22.75%; mutual funds and foreign institutional investors have negligible holdings.

The top shareholders of NGL Fine Chem primarily include the promoters, with Rajesh Lawande holding the largest share at 21.89%. There are no pledged promoter holdings. In terms of public shareholders, Yashkumar Poonamchand Golechha is the highest individual shareholder at 1.05%. Additionally, individual investors collectively hold 22.75% of the company's shares. Mutual funds and foreign institutional investors have minimal holdings, with mutual funds holding 0.0% and only one foreign institutional investor also holding 0.0%.

How big is NGL Fine Chem?

As of 24th July, NGL Fine Chem Ltd has a market capitalization of 791.00 Cr, with net sales of 368.30 Cr and a net profit of 20.85 Cr for the latest four quarters. Shareholder's funds are 262.63 Cr and total assets amount to 355.54 Cr as of March 2024.

As of 24th July, NGL Fine Chem Ltd has a market capitalization of 791.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, NGL Fine Chem reported Net Sales of 368.30 Cr and a Net Profit of 20.85 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 262.63 Cr and Total Assets of 355.54 Cr.

Is NGL Fine Chem overvalued or undervalued?

As of August 4, 2025, NGL Fine Chem is considered overvalued with a PE ratio of 38.04, an EV to EBITDA ratio of 23.60, and a Price to Book Value of 2.81, significantly higher than its peers, while also showing a year-to-date return of -28.62%, lagging behind the Sensex's 3.69%.

As of 4 August 2025, the valuation grade for NGL Fine Chem has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 38.04, an EV to EBITDA ratio of 23.60, and a Price to Book Value of 2.81. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, NGL Fine Chem's PE ratio is higher than Sun Pharma's 34.25 and significantly above Cipla's attractive PE of 22.7. The PEG ratio for NGL Fine Chem is notably low at 0.00, indicating a lack of growth expectations, which further supports the overvaluation claim. Additionally, while the stock has shown strong returns over the long term, its recent performance has lagged behind the Sensex, with a year-to-date return of -28.62% compared to the Sensex's 3.69%.

When is the next results date for NGL Fine Chem?

The next results date for NGL Fine Chem is 12 November 2025.

The next results date for NGL Fine Chem is scheduled for 12 November 2025.

How has been the historical performance of NGL Fine Chem?

NGL Fine Chem has shown an upward trend in net sales and total assets from Mar'20 to Mar'25, increasing from 151.69 Cr to 368.26 Cr, but profitability has declined, with profit after tax dropping from 56.72 Cr in Mar'21 to 21.12 Cr in Mar'25. Overall, while sales and assets have grown, the company faces challenges in maintaining profitability.

Answer:<BR>The historical performance of NGL Fine Chem shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>NGL Fine Chem's net sales have shown a general upward trend, increasing from 151.69 Cr in Mar'20 to 368.26 Cr in Mar'25, despite a dip in Mar'22. Total operating income followed a similar pattern, reaching 368.26 Cr in Mar'25. The raw material cost has also risen significantly, from 69.75 Cr in Mar'20 to 182.41 Cr in Mar'25, contributing to total expenditure growth from 132.30 Cr in Mar'20 to 334.39 Cr in Mar'25. Operating profit (PBDIT) peaked at 87.76 Cr in Mar'21 but has since declined to 42.50 Cr in Mar'25. Profit before tax mirrored this trend, decreasing from 77.59 Cr in Mar'21 to 27.71 Cr in Mar'25. Profit after tax also saw fluctuations, with a high of 56.72 Cr in Mar'21 and a drop to 21.12 Cr in Mar'25. The company's total liabilities increased from 153.62 Cr in Mar'20 to 433.39 Cr in Mar'25, while total assets rose from 153.62 Cr to 433.39 Cr in the same period. Cash flow from operating activities improved to 35.00 Cr in Mar'25, while net cash inflow/outflow remained stable at 0.00 Cr. Overall, NGL Fine Chem has experienced growth in sales and assets, but profitability has faced challenges in recent years.

Is NGL Fine Chem technically bullish or bearish?

As of December 3, 2025, the trend has shifted to mildly bearish due to bearish signals from MACD, KST, Bollinger Bands, and Dow Theory, despite daily moving averages remaining mildly bullish.

As of 3 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by weekly MACD and KST indicators both showing mild bearishness, alongside bearish signals from Bollinger Bands and Dow Theory on a weekly basis. The daily moving averages remain mildly bullish, but the overall trend indicates weakness. The stock has underperformed significantly over the past month and year compared to the Sensex, reinforcing the bearish outlook.

Why is NGL Fine Chem Ltd falling/rising?

As of 02-Feb, NGL Fine Chem Ltd's stock price is rising, currently at 1,737.00, with a year-to-date gain of 23.28% compared to a 4.17% drop in the Sensex. Despite a decline in investor participation, the stock shows strong performance indicators and remains liquid for trading.

As of 02-Feb, NGL Fine Chem Ltd's stock price is rising, currently at 1,737.00, reflecting an increase of 41.95 (2.47%). The stock has shown strong performance over the past week, gaining 15.03%, while the benchmark Sensex has only increased by 0.16%. Over the past month, the stock has risen by 24.93%, contrasting sharply with the Sensex's decline of 4.78%. Year-to-date, NGL Fine Chem has also outperformed the Sensex, with a gain of 23.28% compared to the benchmark's drop of 4.17%.<BR><BR>Today's trading activity indicates a positive trend, as the stock opened with a gain of 3.24% and reached an intraday high of Rs 1,791, representing a 5.66% increase. The stock has been on a consecutive gain streak for the last two days, accumulating a total return of 2.56% during this period. Additionally, NGL Fine Chem is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a bullish indicator.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume on January 30 falling by 35.33% compared to the 5-day average. Despite this drop in participation, the stock remains liquid enough for trading, suggesting that the current rise is supported by strong demand relative to the recent performance metrics. Overall, the combination of significant price increases, strong relative performance against the benchmark, and positive trading indicators contribute to the rising stock price of NGL Fine Chem Ltd.

Which are the latest news on NGL Fine Chem?

Are NGL Fine Chem Ltd latest results good or bad?

NGL Fine Chem Ltd's latest results show strong revenue growth with a 28.65% increase in net sales, but profitability concerns arise from a slight decline in net profit and compressed margins. Overall, while sales performance is impressive, caution is warranted due to challenges in profit generation and high valuation.

NGL Fine Chem Ltd's latest results present a mixed picture. On one hand, the company achieved impressive revenue growth, with net sales reaching ₹120.26 crores, marking a 28.65% increase year-on-year. This is a significant milestone, as it represents the highest quarterly revenue in the company's history. Additionally, the operating margin improved to 14.27%, indicating better operational efficiency.<BR><BR>However, the net profit for the quarter was ₹9.63 crores, which, while showing a slight increase of 4.22% compared to the previous quarter, reflects a decline of 1.83% compared to the same quarter last year. The profit after tax (PAT) margin also compressed to 8.01%, down from 10.49% a year ago, raising concerns about the company's ability to convert sales growth into sustainable profits. <BR><BR>Moreover, the stock has seen a decline of 23.71% over the past year and currently trades significantly below its 52-week high. The valuation appears high at a P/E ratio of 42 times trailing earnings, especially given the deteriorating return ratios and margin pressures.<BR><BR>In summary, while NGL Fine Chem Ltd shows strong revenue momentum, the challenges in profitability and high valuation suggest caution. The results can be seen as good in terms of sales growth but concerning regarding profit margins and overall financial health.

Should I buy, sell or hold NGL Fine Chem Ltd?